Physician profile
Ryan Payne
NPI 1114662632
$573.05
in general payments reported to CMS, 2019-2025
18 companies · $35.24 in 2025
The $35.24 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $86.25 · 2023: $301 · 2024: $151 · 2025: $35.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.56 | 2023-2024 | |
| Abbvie INC. | $60.33 | 2023 | |
| Novo Nordisk INC | $58.78 | 2023 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $50.36 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $42.48 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $36.20 | 2023-2024 | |
| Lundbeck LLC | $33.09 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.29 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $31.24 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $30.54 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $27.67 | 2022-2023 | Mounjaro |
| Inspire Medical Systems, INC. | $19.11 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $16.13 | 2025 | Shingrix |
| Idorsia Pharmaceuticals US INC | $15.69 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $14.82 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14.24 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.04 | 2024 | Voquezna |
| Medtronic, INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.